The Company announced the release, “Notice Concerning the Acquisition of a Newly Established Company that will succeed JSR's in vitro diagnostic pharmaceutical business,” on Apr. 22, 2025.

The documents relating to this matter are as follows.

Notice Concerning the Acquisition of a Newly Established Company that will succeed JSR's in vitro diagnostic pharmaceutical business

Notice Concerning the Acquisition of a Newly Established Company that will succeed JSR’s in vitro diagnostic pharmaceutical business (Presentation)

Q&A